Therapeutic Approaches to the Regulation of Metabolism of High-Density Lipoprotein
Authors:
- 1 January 2013
- journal article
- review article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 77 (11) , 2651-2663
Abstract
High-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles transport cholesterol in plasma and play an important role in cellular cholesterol homeostasis, which influences cell function. The risk of coronary artery disease (CAD) associated with high levels of LDL-cholesterol (LDL-C) can be reduced by treatment with statins, which reduce LDL-C levels by inhibiting cellular cholesterol synthesis. However, patients who are treated with high doses of statins, especially secondary CAD prevention, regardless of their resulting LDL-C levels, are still at high risk of CAD. Therefore, there has been growing interest in HDL-directed therapies. Inhibitors of cholesteryl ester transfer protein (CETP) substantially increase HDL-C levels (by 31-138%). However, it is still unclear whether or not CETP inhibitors can reduce the risk of CAD associated with low HDL-C levels, while reconstituted HDL or apolipoprotein A-I mimetic peptides increase the functionality of HDL. Low levels of HDL-C are often complicated with metabolic disorders, including hypertriglyceridemia, metabolic syndrome, and type 2 diabetes mellitus, and lifestyle changes are effective for correcting these conditions. Physical activity and exercise training increase HDL-C levels, especially HDL2-C levels, by multiple mechanisms. Therefore, although using HDL-directed therapies that increase HDL-C levels and/or improve the function of HDL is a reasonable approach for reducing the residual risk of CAD as a complement to LDL-C-lowering therapy, lifestyle modifications including exercise to improve metabolic disorders should be considered as the first option.Keywords
This publication has 150 references indexed in Scilit:
- Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosisNature Medicine, 2013
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- Adipokines in inflammation and metabolic diseaseNature Reviews Immunology, 2011
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- Nuclear receptors as drug targets for metabolic diseaseAdvanced Drug Delivery Reviews, 2010
- Nutrient-dependent regulation of PGC-1α's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityNature, 2009
- AMPK and the biochemistry of exercise: implications for human health and diseaseBiochemical Journal, 2009
- High-Density Lipoprotein as a Therapeutic TargetJAMA, 2007
- AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1αProceedings of the National Academy of Sciences, 2007